journal article·2023-09-27Open access

Multicolor Photoluminescent Carbon Dots à La Carte for Biomedical Applications

Teodoro Garcia-Millan, Javier Ramos-Soriano, Mattia Ghirardello, Xia Liu, Cristina Manuela Santi, Jean-Charles Eloi, Natalie Pridmore, Robert L. Harniman, David J. Morgan, Stephen Hughes, Sean A. Davis, Thomas A. A. Oliver, Kathreena M. Kurian, M. Carmen Galan

ACS Applied Materials & Interfaces· Volume 15· Issue 38

Abstract

Dual-emission fluorescence probes that provide high sensitivity are key for biomedical diagnostic applications. Nontoxic carbon dots (CDs) are an emerging alternative to traditional fluorescent probes; however, robust and reproducible synthetic strategies are still needed to access materials with controlled emission profiles and improved fluorescence quantum yields (FQYs). Herein, we report a practical and general synthetic strategy to access dual-emission CDs with FQYs as high as 0.67 and green/blue, yellow/blue, or red/blue excitation-dependent emission profiles using common starting materials such as citric acid, cysteine, and co-dopants to bias the synthetic pathway. Structural and physicochemical analysis using nuclear magnetic resonance, absorbance and fluorescence spectroscopy, Fourier-transform infrared spectroscopy, and X-ray photoelectron spectroscopy in addition to transmission electron and atomic force microscopy (TEM and AFM) is used to elucidate the material's composition which is responsible for the unique observed photoluminescence properties. Moreover, the utility of the probes is demonstrated in the clinical setting by the synthesis of green/blue emitting antibody-CD conjugates which are used for the immunohistochemical staining of human brain tissues of glioblastoma patients, showing detection under two different emission channels.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Carbon and Quantum Dots Applications · Nanocluster Synthesis and Applications · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Chemistry, University of Bristol, Cantock’s Close, Bristol BS8 1TS, U.K.

Bristol Medical School, Public Health Sciences, Southmead Hospital, University of Bristol, Southmead Road, Bristol BS8 NB, U.K.

Cardiff Catalysis Institute, Cardiff University, Park Place, Cardiff CF10 3AT, U.K.

HarwellXPS─The EPSRC National Facility for Photoelectron, Spectroscopy, Research Complex at Harwell (RCaH), Didcot OX11 0FA, U.K.

DST Innovations Ltd, Unit 6a Bridgend Business Centre, Bennett Street, Bridgend CF31 3SH, U.K.

Funding

Royal Society · H2020 Marie Sklodowska-Curie Actions · EPSRC Centre for Doctoral Training in Additive Manufacturing · H2020 European Research Council · Cancer Research UK

References (76)

Show source-provided references
1. 10.1088/0953-8984/25/19/19410110.1088/0953-8984/25/19/194101 ↗
2. 10.1016/j.mtadv.2019.10003610.1016/j.mtadv.2019.100036 ↗
3. 10.1021/jp911539r10.1021/jp911539r ↗
4. 10.1088/1468-6996/13/4/04500810.1088/1468-6996/13/4/045008 ↗
5. 10.1002/anie.20090065210.1002/anie.200900652 ↗
6. 10.1016/j.snb.2015.02.10410.1016/j.snb.2015.02.104 ↗
7. 10.1007/s00604-018-2953-910.1007/s00604-018-2953-9 ↗
8. 10.1021/acsami.8b0883210.1021/acsami.8b08832 ↗
9. 10.1039/c4cs00269e10.1039/c4cs00269e ↗
10. 10.1002/anie.20090662310.1002/anie.200906623 ↗
11. 10.1039/c9qm00618d10.1039/c9qm00618d ↗
12. 10.1016/j.trac.2017.02.00110.1016/j.trac.2017.02.001 ↗
13. 10.1039/c9nr05647e10.1039/c9nr05647e ↗
14. 10.3390/nano1108187710.3390/nano11081877 ↗
15. 10.1021/ja040082h10.1021/ja040082h ↗
16. 10.1016/j.jcat.2016.09.00610.1016/j.jcat.2016.09.006 ↗
17. 10.1016/j.carbon.2013.10.02310.1016/j.carbon.2013.10.023 ↗
18. 10.1016/j.biomaterials.2012.01.05210.1016/j.biomaterials.2012.01.052 ↗
19. 10.1039/c4nj00840e10.1039/c4nj00840e ↗
20. 10.1039/c5ra24621k10.1039/c5ra24621k ↗
21. 10.1002/nano.20210018310.1002/nano.202100183 ↗
22. 10.1002/adma.20150032310.1002/adma.201500323 ↗
23. 10.1016/j.ijpharm.2019.04.05510.1016/j.ijpharm.2019.04.055 ↗
24. 10.1111/nph.1688610.1111/nph.16886 ↗
25. 10.1039/c9qm00614a10.1039/c9qm00614a ↗
26. 10.1098/rsfs.2018.004810.1098/rsfs.2018.0048 ↗
27. 10.1039/d2cs00741j10.1039/d2cs00741j ↗
28. 10.1039/c7cs00235a10.1039/c7cs00235a ↗
29. 10.1016/j.nantod.2018.02.00810.1016/j.nantod.2018.02.008 ↗
30. 10.1002/anie.20170094910.1002/anie.201700949 ↗
31. 10.1039/c2jm34690g10.1039/c2jm34690g ↗
32. 10.1002/wnan.161710.1002/wnan.1617 ↗
33. 10.1002/smll.20190576710.1002/smll.201905767 ↗
34. 10.1002/advs.20190131610.1002/advs.201901316 ↗
35. 10.1039/d2nr01306a10.1039/d2nr01306a ↗
36. 10.1016/j.polymer.2017.02.03910.1016/j.polymer.2017.02.039 ↗
37. 10.1039/c6cp05321a10.1039/c6cp05321a ↗
38. 10.1039/c8gc02736f10.1039/c8gc02736f ↗
39. 10.1039/c8nr03430c10.1039/c8nr03430c ↗
40. 10.1039/c8nr00204e10.1039/c8nr00204e ↗
41. 10.1088/1361-6528/aab9d610.1088/1361-6528/aab9d6 ↗
42. 10.1039/c7nr03570e10.1039/c7nr03570e ↗
43. 10.1002/smll.20170209810.1002/smll.201702098 ↗
44. 10.1021/acsami.5b1157910.1021/acsami.5b11579 ↗
45. 10.1021/acs.jpclett.7b0015310.1021/acs.jpclett.7b00153 ↗
46. 10.1063/1.514381910.1063/1.5143819 ↗
47. 10.1002/adma.20170591310.1002/adma.201705913 ↗
48. 10.1002/adma.20150489110.1002/adma.201504891 ↗
49. 10.1021/acsnano.7b0639910.1021/acsnano.7b06399 ↗
50. 10.1021/acs.jpcc.5b0851610.1021/acs.jpcc.5b08516 ↗
51. The James Lind Alliance. Neuro-oncology Top 10 Priorities, 2022. http://www.jla.nihr.ac.uk/priority-setting-partnerships/neurooncology/top-10-priorities/ (accessed May 23, 2023).
52. 10.3109/02688697.2014.95063110.3109/02688697.2014.950631 ↗
53. 10.3389/fonc.2021.74381410.3389/fonc.2021.743814 ↗
54. 10.1039/d2na00060a10.1039/d2na00060a ↗
55. 10.1016/s1387-2656(05)11007-210.1016/s1387-2656(05)11007-2 ↗
56. 10.1016/j.snb.2021.13046510.1016/j.snb.2021.130465 ↗
57. 10.1021/acsami.0c0028310.1021/acsami.0c00283 ↗
58. 10.1039/c9nj02806d10.1039/c9nj02806d ↗
59. 10.1039/c6nr07336k10.1039/c6nr07336k ↗
60. 10.1038/s41598-018-29674-210.1038/s41598-018-29674-2 ↗
61. 10.1016/j.carbon.2017.03.06110.1016/j.carbon.2017.03.061 ↗
62. 10.1038/srep0529410.1038/srep05294 ↗
63. 10.1021/acs.jpcc.6b1251910.1021/acs.jpcc.6b12519 ↗
64. 10.1002/anie.20130748110.1002/anie.201307481 ↗
65. 10.1039/c6nr00451b10.1039/c6nr00451b ↗
66. 10.1021/acsabm.9b0037410.1021/acsabm.9b00374 ↗
67. 10.1039/d1nr01693h10.1039/d1nr01693h ↗
68. 10.1021/acs.jpcc.9b1173210.1021/acs.jpcc.9b11732 ↗
69. 10.1039/c8nr02953a10.1039/c8nr02953a ↗
70. 10.1021/acs.nanolett.7b0386310.1021/acs.nanolett.7b03863 ↗
71. 10.1039/c5tc00813a10.1039/c5tc00813a ↗
72. 10.1007/s12274-014-0644-310.1007/s12274-014-0644-3 ↗
73. 10.1039/d1nr02763h10.1039/d1nr02763h ↗
74. 10.1007/s11060-015-1978-810.1007/s11060-015-1978-8 ↗
75. 10.1021/acs.accounts.6b0029210.1021/acs.accounts.6b00292 ↗
76. 10.1002/cyto.99013080610.1002/cyto.990130806 ↗